Evotec SE (XETRA:EVT) — Market Cap & Net Worth
Market Cap & Net Worth: Evotec SE (EVT)
Evotec SE (XETRA:EVT) has a market capitalization of $804.48 Million (€688.12 Million) as of May 4, 2026. Listed on the XETRA stock exchange, this Germany-based company holds position #10127 globally and #1201 in its home market, demonstrating a -7.83% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Evotec SE's stock price €5.24 by its total outstanding shares 177746121 (177.75 Million). Analyse cash flow conversion of Evotec SE to see how efficiently the company converts income to cash.
Evotec SE Market Cap History: 2015 to 2026
Evotec SE's market capitalization history from 2015 to 2026. Data shows growth from $866.54 Million to $1.09 Billion (2.60% CAGR).
Index Memberships
Evotec SE is a constituent of 4 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
HDAX Performance
GDAXHI
|
$1.23 Trillion | 0.07% | #56 of 99 |
|
HDAX Price
GDAXHIP
|
$1.25 Trillion | 0.06% | #58 of 102 |
|
DAX Midcap
MDAXI
|
$190.09 Billion | 0.42% | #32 of 49 |
|
DAX Midcap Price
MKDX
|
$183.83 Billion | 0.44% | #32 of 50 |
Weight: Evotec SE's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Evotec SE Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Evotec SE's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.44x
Evotec SE's market cap is 1.44 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.55 Billion | $164.51 Million | $27.53 Million | 9.40x | 56.17x |
| 2017 | $2.81 Billion | $257.63 Million | $24.26 Million | 10.89x | 115.65x |
| 2018 | $3.61 Billion | $375.40 Million | $84.17 Million | 9.61x | 42.87x |
| 2019 | $4.79 Billion | $446.44 Million | $38.16 Million | 10.73x | 125.53x |
| 2020 | $6.29 Billion | $500.92 Million | $6.28 Million | 12.56x | 1002.28x |
| 2021 | $8.83 Billion | $618.03 Million | $215.51 Million | 14.29x | 40.98x |
| 2022 | $3.17 Billion | $751.45 Million | -$175.66 Million | 4.22x | N/A |
| 2023 | $4.42 Billion | $781.43 Million | -$83.91 Million | 5.66x | N/A |
| 2024 | $1.70 Billion | $796.97 Million | -$196.08 Million | 2.14x | N/A |
| 2025 | $1.13 Billion | $788.37 Million | -$103.52 Million | 1.44x | N/A |
Competitor Companies of EVT by Market Capitalization
Companies near Evotec SE in the global market cap rankings as of May 4, 2026.
Key companies related to Evotec SE by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #499 globally with a market cap of $52.60 Billion USD.
- Zoetis Inc (NYSE:ZTS): Ranked #525 globally with a market cap of $50.31 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #526 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #572 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #499 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #525 | Zoetis Inc | NYSE:ZTS | $50.31 Billion | $114.16 |
| #526 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.29 Billion | CN¥53.88 |
| #572 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $42.15 |
Evotec SE Historical Marketcap From 2015 to 2026
Between 2015 and today, Evotec SE's market cap moved from $866.54 Million to $ 1.09 Billion, with a yearly change of 2.60%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €1.09 Billion | -3.85% |
| 2025 | €1.13 Billion | -33.50% |
| 2024 | €1.70 Billion | -61.49% |
| 2023 | €4.42 Billion | +39.45% |
| 2022 | €3.17 Billion | -64.09% |
| 2021 | €8.83 Billion | +40.36% |
| 2020 | €6.29 Billion | +31.37% |
| 2019 | €4.79 Billion | +32.74% |
| 2018 | €3.61 Billion | +28.63% |
| 2017 | €2.81 Billion | +81.40% |
| 2016 | €1.55 Billion | +78.47% |
| 2015 | €866.54 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Evotec SE was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $804.48 Million USD |
| MoneyControl | $804.48 Million USD |
| MarketWatch | $804.48 Million USD |
| marketcap.company | $804.48 Million USD |
| Reuters | $804.48 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Evotec SE
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just " Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammati… Read more